On May 2, 2022 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report financial and business results for the first quarter of 2022 after the market closes on Monday, May 9, 2022 (Press release, Supernus, MAY 2, 2022, View Source [SID1234613296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2022 financial and business results on Monday, May 9, 2022 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be available in the Events & Presentations section of the Supernus website at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference Call Name: Supernus Pharmaceuticals First Quarter 2022 Results Conference Call
Following the live call, a replay will be available on the Company’s website, www.supernus.com, in the Investor Relations section. The webcast will be available on the Company’s website for 60 days following the live call.

On May 2, 2022 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that it will participate in the Goldman Sachs Industrials and Materials Conference being held in New York, NY (Press release, Leidos, MAY 2, 2022, View Source [SID1234613312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chris Cage, Chief Financial Officer, will engage in a question and answer "fireside chat" on Tuesday, May 10, 2022 at 9:40 a.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for one year afterward.

On May 2, 2022 Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, reported that the Company will present at the upcoming ASGCT (Free ASGCT Whitepaper) 25th Annual Meeting, taking place May 16-19, 2022, in Washington, D.C (Press release, Athenex, MAY 2, 2022, View Source [SID1234613349]). The abstract associated with the presentation is now available on the conference website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentations are as follows:

Oral Presentation Details

Abstract 54: Anti-GD2 CAR NKT cells are safe and produce antitumor responses in patients with relapsed/refractory neuroblastoma
Date/Time: Monday, May 16, 2022, 2:30 PM – 2:45 PM ET
Session: Gene and Cell Therapy Trials in Progress
Presenter: Dr. Andras Heczey, Baylor College of Medicine
Location: Room 201, Walter E. Washington Convention Center, 801 Mt Vernon Pl NW Washington, D.C.

"Observing evidence of a dose response is extremely encouraging, and we are excited to see two out of three responses at 100 million cells/m2," said Dan Lang, M.D., President of Athenex Cell Therapy. "We are hopeful that we will see additional responses as we move to higher doses. We and our partners at Baylor College of Medicine (BCM) and Texas Children’s Hospital (TCH) continue to be motivated by the data and look forward to our next update."

About KUR-501

KUR-501, is an autologous NKT cell CAR product that targets GD2, a tumor-associated antigen that is expressed on almost all neuroblastomas as well as melanomas, some sarcomas, and a variety of other tumors. GINAKIT2, a phase 1 single arm clinical study (NCT03294954) of KUR-501, in patients with refractory or recurrent high-risk neuroblastoma will evaluate up to six dose levels of KUR-501 following lymphodepletion with cyclophosphamide and fludarabine.

Neuroblastoma, a pediatric cancer of the sympathetic nervous system, typically the adrenal gland, is associated with a poor prognosis in children with high-risk disease and is a significant unmet medical need. The KUR-501 development program will provide autologous proof-of-concept for CAR-NKT cells in solid tumors using a validated target.

The GINAKIT2 study is supported by Athenex, Inc., which acquired Kuur Therapeutics in May 2021, as well as by Alex’s Lemonade Stand Foundation. This study is currently recruiting patients at BCM/TCH.

On May 2, 2022 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, reported that it will present a poster at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo, May 2-5 (Press release, iBioPharma, MAY 2, 2022, View Source [SID1234614060]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rachel Jordan, PhD, a senior product manager at iBio, will present the poster (#P061), titled "Plant-Made Antibodies Show Superior Glycosylation Homogeneity While Retaining Pharmacokinetic Properties," which highlights:

The production of a single uniform G0 glycosylation pattern, lacking fucose and xylose, of NISTmAb and rituximab when compared to Chinese Hamster Ovary (CHO) cell culture produced antibodies, which contain more heterogeneous glycosylation patterns.
Comparability of in vivo rodent pharmacokinetic profiles for NISTmAb and rituximab produced using mammalian cell culture and the FastPharming System.
How rapid, scalable transient expression in plants of high-quality mAbs for in vivo studies can significantly shorten the time to achieve in vivo proof-of-concept.
More information about producing consistent, high-quality antibodies in the FastPharming System may be accessed in a whitepaper here.

On May 2, 2022 The board of directors of Eli Lilly and Company (NYSE: LLY) reported that it has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock (Press release, Eli Lilly, MAY 2, 2022, View Source [SID1234613281]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dividend is payable on June 10, 2022 to shareholders of record at the close of business on May 16, 2022.